ML133 HCl: Selective Kir2.1 Channel Blocker for Cardiovascular Research

Executive Summary: ML133 HCl (SKU B2199) is a potent and selective inhibitor for Kir2.1 potassium channels, with an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5, and shows negligible activity against Kir1.1, Kir4.1, and Kir7.1 (APExBIO, product page). ML133 HCl blocks Kir2.1-mediated potassium ion transport, thereby inhibiting pulmonary artery smooth muscle cell (PASMC) proliferation and migration, both in vitro and in vivo (Cao et al., 2022). The compound is insoluble in water, but displays high solubility in DMSO (≥15.7 mg/mL) and ethanol (≥2.52 mg/mL) under gentle warming and ultrasonication. ML133 HCl is widely used in cardiovascular disease models to dissect Kir2.1 function and downstream TGF-β1/SMAD2/3 signaling. It is supplied as a solid and should be stored at -20°C for optimal stability (APExBIO, product page).

Biological Rationale

Kir2.1 channels (gene: KCNJ2) regulate resting membrane potential and potassium ion conductance in excitable and non-excitable cells (Cao et al., 2022). Upregulation of Kir2.1 expression is observed in pulmonary hypertension (PH) models, contributing to the abnormal proliferation and migration of PASMCs, which drive vascular remodeling in PH. Targeting Kir2.1 is therefore a strategic intervention point for modulating vascular smooth muscle cell behavior and addressing cardiovascular disease mechanisms. Selective inhibition of Kir2.1, unlike non-specific potassium channel blockers, allows researchers to probe specific downstream pathways such as TGF-β1/SMAD2/3, OPN, and PCNA expression, which are implicated in pathological remodeling (Cao et al., 2022).

Mechanism of Action of ML133 HCl

ML133 HCl is the hydrochloride salt of 1-(4-methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine (C₁₉H₁₉NO·HCl, MW: 313.82). This compound selectively binds to Kir2.1 channels, blocking inward potassium currents. Inhibition is concentration- and pH-dependent: IC₅₀ = 1.8 μM at pH 7.4, and 290 nM at pH 8.5 (APExBIO). ML133 HCl does not inhibit Kir1.1 and only weakly inhibits Kir4.1 and Kir7.1, making it suitable for dissecting Kir2.1-specific roles. By blocking Kir2.1, ML133 HCl hyperpolarizes cell membranes and impairs downstream signaling cascades, including the TGF-β1/SMAD2/3 pathway, which controls PASMC proliferation, migration, and extracellular matrix deposition (Cao et al., 2022).

Evidence & Benchmarks

• ML133 HCl (10 μM, 24 h pre-treatment) inhibits PDGF-BB-induced proliferation and migration in human PASMCs, as measured by scratch and transwell assays (Cao et al., 2022).
• Kir2.1 expression and TGF-β1/SMAD2/3 signaling are upregulated in monocrotaline-induced PH rat models; ML133 HCl reverses these molecular changes (Cao et al., 2022).
• ML133 HCl shows no significant inhibition of Kir1.1 channels in patch-clamp assays at concentrations up to 10 μM (APExBIO).
• In PASMC assays, ML133 HCl suppresses OPN and PCNA protein expression, key mediators of cell proliferation and migration (Cao et al., 2022).
• ML133 HCl is insoluble in water but dissolves ≥15.7 mg/mL in DMSO and ≥2.52 mg/mL in ethanol with gentle warming and ultrasonication (APExBIO).

Applications, Limits & Misconceptions

ML133 HCl is extensively used to dissect Kir2.1 function in pulmonary artery and cardiovascular research. It enables precise modulation of potassium ion transport and downstream signaling in cellular and animal models. Researchers leverage ML133 HCl in PASMC proliferation/migration assays, vascular remodeling studies, and for validating Kir2.1 as a therapeutic target (Cao et al., 2022).

For a thorough protocol-focused discussion and troubleshooting scenarios, see this article. This current review extends the previous by offering a consolidated, evidence-based synthesis and cross-referencing major benchmarks.

For mechanistic and translational perspectives, this strategic analysis outlines the broader roadmap for Kir2.1-targeted disease models; the current article updates those findings with the latest peer-reviewed data.

For integration in cardiovascular disease modeling, this article explores downstream signaling, while the present review prioritizes direct experimental benchmarks and product-specific guidance.

Common Pitfalls or Misconceptions

• ML133 HCl does not inhibit Kir1.1 channels at physiologically relevant concentrations (APExBIO).
• ML133 HCl is not water-soluble; improper solvent selection leads to precipitation and assay variability.
• Long-term storage of ML133 HCl in solution decreases potency; only prepare fresh stocks for each experiment.
• ML133 HCl is selective for Kir2.1 and may not reproduce effects seen with non-selective potassium channel blockers.
• In vivo effects may vary based on disease model and administration route; always confirm tissue/plasma concentrations.

Workflow Integration & Parameters

ML133 HCl is supplied as a solid by APExBIO and should be stored at -20°C. For experimental use, dissolve in DMSO (≥15.7 mg/mL) or ethanol (≥2.52 mg/mL) with gentle warming/ultrasonication. Typical working concentrations range from 0.3–10 μM in cell-based assays. Avoid repeated freeze-thaw cycles and long-term storage of solutions. For PASMC assays, pre-treat cells with ML133 HCl for 24 hours before induction with PDGF-BB. Validate inhibition via electrophysiology or downstream marker expression (e.g., OPN, PCNA, TGF-β1/SMAD2/3). For cardiovascular disease models, consult product documentation and recent literature for optimal dosing and schedule (Cao et al., 2022; APExBIO).

Conclusion & Outlook

ML133 HCl, as offered by APExBIO, provides a rigorously validated, highly selective tool for Kir2.1 channel inhibition. Its utility in PASMC proliferation, migration, and vascular remodeling studies is supported by robust peer-reviewed evidence (Cao et al., 2022). ML133 HCl enables precise analysis of potassium ion transport and downstream signaling in cardiovascular disease models. For researchers requiring reproducibility and selectivity in Kir2.1 experiments, ML133 HCl (B2199) represents a gold-standard reagent. Ongoing development of Kir2.1-targeted interventions may further expand the translational impact of ML133 HCl in cardiovascular and pulmonary research.